Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Fischetti

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Autoimmunity Reviews|October 27, 2010
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritisMartina Fabris, Luca Quartuccio, Sandra Lombardi, et al.
Clinical and Experimental Rheumatology|September 6, 2022
The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmodFausto Salaffi, Marco Di Carlo, Sonia Farah, et al.
Annals of the Rheumatic Diseases|March 19, 2013
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre studyLuca Quartuccio, Martina Fabris, Elena Pontarini, et al.
Arthritis and Rheumatism|September 25, 2012
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockersMartina Fabris, Luca Quartuccio, Ed Vital, et al.
Clinical and Experimental Rheumatology|May 4, 2023
Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based studyFausto Salaffi, Marco Di Carlo, Manuela Di Franco, et al.
Thrombosis and Haemostasis|March 16, 2022
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS)Savino Sciascia, Silvia Grazietta Foddai, Cristiano Alessandri, et al.
Thrombosis and Haemostasis|May 24, 2023
Erratum: Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS)Savino Sciascia, Silvia Grazietta Foddai, Cristiano Alessandri, et al.
Rheumatology Advances in Practice|August 4, 2021
The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patientsFabiola Atzeni, Alessandra Alciati, Fausto Salaffi, et al.
Clinical and Experimental Rheumatology|June 24, 2022
Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia RegistryFabiola Atzeni, Alessandra Alciati, Laura Bazzichi, et al.
Rheumatology (Oxford, England)|August 15, 2020
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patientsFausto Salaffi, Marco Di Carlo, Laura Bazzichi, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Autoimmunity Reviews|October 27, 2010
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritisMartina Fabris, Luca Quartuccio, Sandra Lombardi, et al.
Clinical and Experimental Rheumatology|September 6, 2022
The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmodFausto Salaffi, Marco Di Carlo, Sonia Farah, et al.
Annals of the Rheumatic Diseases|March 19, 2013
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre studyLuca Quartuccio, Martina Fabris, Elena Pontarini, et al.
Arthritis and Rheumatism|September 25, 2012
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockersMartina Fabris, Luca Quartuccio, Ed Vital, et al.
Clinical and Experimental Rheumatology|May 4, 2023
Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based studyFausto Salaffi, Marco Di Carlo, Manuela Di Franco, et al.
Thrombosis and Haemostasis|March 16, 2022
Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS)Savino Sciascia, Silvia Grazietta Foddai, Cristiano Alessandri, et al.
Thrombosis and Haemostasis|May 24, 2023
Erratum: Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS)Savino Sciascia, Silvia Grazietta Foddai, Cristiano Alessandri, et al.
Rheumatology Advances in Practice|August 4, 2021
The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patientsFabiola Atzeni, Alessandra Alciati, Fausto Salaffi, et al.
Clinical and Experimental Rheumatology|June 24, 2022
Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia RegistryFabiola Atzeni, Alessandra Alciati, Laura Bazzichi, et al.
Rheumatology (Oxford, England)|August 15, 2020
Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patientsFausto Salaffi, Marco Di Carlo, Laura Bazzichi, et al.
Pageof 3